Aelis Farma (FRA:69O) 1-Year Sharpe Ratio: -0.60 (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:69O Aelis Farma SA FRA:69O
32 GF Score
Price €0.96
GF Value €0.94
! 4 Warning Signs
View Full Analysis

What is Aelis Farma 1-Year Sharpe Ratio?

Aelis Farma FRA:69O -0.83% 32 1-Year Sharpe Ratio is -0.60 as of Sep. 02, 2026. GuruFocus rates FRA:69O with a GF Score™ of 32/100 and a GF Value™ of €0.94. The stock has 4 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-02), Aelis Farma's 1-Year Sharpe Ratio is -0.60.

Aelis Farma  (FRA:69O) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Aelis Farma 1-Year Sharpe Ratio Related Terms

FRA:69O vs VRTX, REGN, MRNA: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Aelis Farma's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aelis Farma 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aelis Farma's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Aelis Farma's 1-Year Sharpe Ratio falls into.


FRA:69O
32GF Score
Aelis Farma SA FRA:69O
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aelis Farma 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.60 mean?
Aelis Farma (FRA:69O) has a 1-Year Sharpe Ratio of -0.60 as of Sep. 02, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Aelis Farma and its competitors.
Is Aelis Farma's 1-Year Sharpe Ratio too high?
Aelis Farma's current 1-Year Sharpe Ratio is -0.60. Overall, Aelis Farma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Aelis Farma's 1-Year Sharpe Ratio compare to VRTX and REGN?
Aelis Farma's 1-Year Sharpe Ratio of -0.60 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Aelis Farma and its competitors. Aelis Farma's current 1-Year Sharpe Ratio is -0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aelis Farma stock overvalued right now?
Aelis Farma (FRA:69O) has a current 1-Year Sharpe Ratio of -0.60. The stock's GF Value™ is €0.94, compared to a current price of €0.96 — trading 2.1% above its estimated fair value. The current 1-Year Sharpe Ratio is -0.60. Aelis Farma's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Aelis Farma (FRA:69O), the current 1-Year Sharpe Ratio is -0.60 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aelis Farma (FRA:69O) Overvalued in 2026?

Based on GuruFocus' analysis, Aelis Farma stock appears to be overvalued. The current stock price of €0.96 is trading 2.1% above its estimated GF Value™ of €0.94.

Key valuation signals for FRA:69O:

  • 1-Year Sharpe Ratio: -0.60
  • GF Value™: €0.94 vs. price of €0.96 (2.1% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the FRA:69O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aelis Farma Business Description

Other Exchanges AELIS:France
Address 2 rue Robert Escarpit, IECB, Pessac, Bordeaux, FRA, 33607
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases. The Company operates in only one business segment: the research and development of pharmaceutical products.
32GF Score

Get the complete analysis for FRA:69O

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.96
Price
€0.94
GF Value